JP2024510975A - 前立腺癌を処置する方法 - Google Patents

前立腺癌を処置する方法 Download PDF

Info

Publication number
JP2024510975A
JP2024510975A JP2023555527A JP2023555527A JP2024510975A JP 2024510975 A JP2024510975 A JP 2024510975A JP 2023555527 A JP2023555527 A JP 2023555527A JP 2023555527 A JP2023555527 A JP 2023555527A JP 2024510975 A JP2024510975 A JP 2024510975A
Authority
JP
Japan
Prior art keywords
prostate cancer
compound
cells
acid
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510975A5 (cg-RX-API-DMAC7.html
Inventor
マラテスタ,マルティナ
ホープ フィルバロフ,エレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2024510975A publication Critical patent/JP2024510975A/ja
Publication of JP2024510975A5 publication Critical patent/JP2024510975A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023555527A 2021-03-12 2022-03-10 前立腺癌を処置する方法 Pending JP2024510975A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163160319P 2021-03-12 2021-03-12
US63/160,319 2021-03-12
PCT/US2022/019662 WO2022192481A1 (en) 2021-03-12 2022-03-10 Methods of treating prostate cancer

Publications (2)

Publication Number Publication Date
JP2024510975A true JP2024510975A (ja) 2024-03-12
JP2024510975A5 JP2024510975A5 (cg-RX-API-DMAC7.html) 2025-03-18

Family

ID=80952117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555527A Pending JP2024510975A (ja) 2021-03-12 2022-03-10 前立腺癌を処置する方法

Country Status (7)

Country Link
US (1) US12016847B2 (cg-RX-API-DMAC7.html)
EP (1) EP4304589B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024510975A (cg-RX-API-DMAC7.html)
KR (1) KR20230156107A (cg-RX-API-DMAC7.html)
CN (1) CN117241797A (cg-RX-API-DMAC7.html)
ES (1) ES3076129T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022192481A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505762A (ja) * 2013-12-24 2017-02-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗がん剤としての三環式化合物
JP2017511801A (ja) * 2014-02-28 2017-04-27 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン BETブロモドメイン阻害剤としての9H−ピリミド[4,5−b]インドールおよび関連類似体
JP2017537166A (ja) * 2014-12-05 2017-12-14 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 癌免疫療法におけるアジュバントとしてのブロモドメイン阻害剤
WO2017216772A2 (en) * 2016-06-16 2017-12-21 The University Of Chicago Methods and compositions for treating breast and prostate cancer
WO2019080941A1 (en) * 2017-10-27 2019-05-02 Jacobio-Beta Pharmaceuticals Co., Ltd. NEW TRICYCLIC COMPOUNDS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073923A1 (es) 2008-10-31 2010-12-09 Medivation Technologies Inc Pirido( 4,3-b) indoles que contienen restos rigidos
CN102257076B (zh) 2008-12-18 2014-07-30 纳幕尔杜邦公司 具有新颜料的粉末涂料组合物
US8580399B2 (en) 2011-04-08 2013-11-12 Universal Display Corporation Substituted oligoazacarbazoles for light emitting diodes
KR20140068883A (ko) 2011-09-28 2014-06-09 이데미쓰 고산 가부시키가이샤 유기 전계 발광 소자용 재료 및 이를 사용한 유기 전계 발광 소자
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2961747B1 (en) 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
US9458156B2 (en) * 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505762A (ja) * 2013-12-24 2017-02-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗がん剤としての三環式化合物
JP2017511801A (ja) * 2014-02-28 2017-04-27 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン BETブロモドメイン阻害剤としての9H−ピリミド[4,5−b]インドールおよび関連類似体
JP2017537166A (ja) * 2014-12-05 2017-12-14 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 癌免疫療法におけるアジュバントとしてのブロモドメイン阻害剤
WO2017216772A2 (en) * 2016-06-16 2017-12-21 The University Of Chicago Methods and compositions for treating breast and prostate cancer
WO2019080941A1 (en) * 2017-10-27 2019-05-02 Jacobio-Beta Pharmaceuticals Co., Ltd. NEW TRICYCLIC COMPOUNDS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FAIVRE EMILY J.: "Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel", MOLECULAR CANCER RESEARCH, vol. 15(1), JPN7026000887, 2017, pages 35 - 44, ISSN: 0005807926 *
谷内出友美: "BETブロモドメインを標的としたエピジェネティクス制御", MEDCHEM NEWS, vol. 27(4), JPN7026000886, 2017, pages 213 - 218, ISSN: 0005807925 *

Also Published As

Publication number Publication date
ES3076129T3 (en) 2026-08-12
US20220296574A1 (en) 2022-09-22
KR20230156107A (ko) 2023-11-13
WO2022192481A1 (en) 2022-09-15
US12016847B2 (en) 2024-06-25
EP4304589A1 (en) 2024-01-17
CN117241797A (zh) 2023-12-15
EP4304589B1 (en) 2026-06-17
EP4304589C0 (en) 2026-06-17

Similar Documents

Publication Publication Date Title
US20220265618A1 (en) Methods of treating prostate cancer
EP3704108B1 (en) Irak4 inhibitor in combination with a bcl-2 inhibitor for use in treating cancer
ES2981521T3 (es) Compuestos y procedimientos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales
PT1024814E (pt) Utilização de agentes antifúngicos para o tratamento tópico de mucosite induzida por fungo
ES2376493T3 (es) Procedimiento para reducir o aliviar la inflamación en el tubo digestivo.
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
WO2008122190A1 (en) The composition comprising l-carnitine or derivatives thereof and its use
US12016847B2 (en) Methods of treating prostate cancer
US20120045433A1 (en) Combination therapy
TW201919618A (zh) 用於治療肉瘤的化合物
US8785423B2 (en) Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
AU2019354771A1 (en) Combination therapy for the treatment of uveal melanoma
RU2423692C2 (ru) Вещества для профилактики и лечения панкреатита
CN115884775A (zh) 用于治疗真菌感染的化合物及方法
CN116650490B (zh) 化合物mt-1207在降低尿酸方面的应用
KR102740381B1 (ko) 벤즈이미다졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
HK40099691A (en) Bromodomain (bet) inhibitor for use in treating prostate cancer
TW202408469A (zh) 醫藥組合物及其用途
US20100204286A1 (en) Method for reducing gastrointestinal adverse effects of cytotoxic agents
JP2019517506A (ja) 血管破壊剤を含む肝臓癌治療用の組成物
CN106580938A (zh) 一种氨丁三醇有机酸盐及其制备方法和应用
US20220062247A1 (en) Use of a par-1 antagonist for the treatment of a chronic inflammatory intestinal disease
WO2006046746A1 (ja) 内臓痛予防・治療剤
CN115364083B (zh) 一种利多卡因衍生物在制备防治肠道屏障损伤产品中的应用
JP2015003902A (ja) 血管新生阻害剤

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260601